Age at onset of MAC, yrs ± SD
|
57 ± 12
|
Age (when found to be resistant), yrs ± SD
|
67 ± 9
|
Female, n (%)
|
31 (93.9)
|
Body mass index, kg/m2 ± SD
|
17.2 ± 5.0
|
Smoking history, n (%)
| |
Current/Former/Never
|
0 (0)/3 (9.1)/30 (90.9)
|
Pack-years ≥20, n (%)
|
1 (3.0)
|
Alcohol abuse, n (%)
|
1 (3.0)
|
Underlying respiratory disease, n (%)
| |
Old pulmonary tuberculosis
|
2 (6.1)
|
Bronchiectasis
|
2 (6.1)
|
Interstitial pneumonia
|
1 (3.0)
|
Underlying systematic disease, n (%)
| |
Old cerebral infarction
|
1 (3.0)
|
Diabetes mellitus
|
1 (3.0)
|
Radiographic features, n (%)
| |
NB/FC
|
8 (24.2)/25 (75.8)
|
Total lesion extenta 1/2/3, n (%)
|
2 (6.1)/24 (72.7)/7 (21.2)
|
Cavity at the beginning of treatment, n (%)
|
25 (75.8)
|
Laboratory
| |
White blood cell, /μl ± SD
|
5590 ± 1437
|
Neutrophil, /μl ± SD
|
3915 ± 1291
|
Hemoglobin, g/dl ± SD
|
12.4 ± 1.3
|
Serum albumin, g/dl ± SD
|
3.8 ± 0.6
|
CRP, mg/dl ± SD
|
1.9 ± 2.9
|
AST, mg/dl ± SD
|
23 ± 7
|
ALT, mg/dl ± SD
|
15.9 ± 8.4
|
Cre, mg/dl ± SD
|
0.5 ± 0.14
|
Chronic infection with P. aeruginosa
|
3 (9.1)
|
With treatment for pulmonary aspergillosis, n (%)
|
4 (12.1)
|
Steroid use, n (%)
|
0 (0)
|
Past MAC treatment
| |
CAM monotherapy, n (%)
|
6 (18.2)
|
Two-drug regimen including CAM, n (%)
|
4 (12.1)
|
MAC treatment more than 5 years, n (%)
|
20 (60.6)
|